This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Method of action

Authoring team

  • selectively block the action of leukotrienes on the respiratory tract. Leukotriene antagonists result in a reduction in mucus secretion, vascular permeability, and bronchoconstriction. There is also a reduction in eosinophil recruitment. Leukotriene antagonists result in an inhibition in early and late stage bronchoconstriction - indicating both a bronchodilatory and anti-inflammatory role

  • there is no evidence to suggest that leukotriene antagonists provide protection against aspirin- or NSAID - induced anaphylaxis. Neither is there evidence that leukotriene antagonists benefit aspirin-sensitive asthmatics more than those without aspirin sensitivity.

Reference:

  • MeReC Bulletin (1999), 1, 1-4.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.